On July 10-12, 2024, our group had the pleasure of hosting Dr. Tirdad Seifi Ala, our esteemed partner from the Danish Medicines Agency (Lægemiddelstyrelsen, DMA), for an in-depth technical meeting within the REDDIE project. This visit was a significant milestone in our ongoing collaboration and provided an excellent opportunity to delve into the details of the current activities in Work Package 5 (WP5), titled “Advanced Methodological Frameworks for Enhancing Clinical Trials with Real-World and Virtual Evidence.”
The WP5 is led by our research group under the supervision of Principal Investigator Dr. Martina Vettoretti, with active involvement from both UNIPD and DMA. During the meeting, we had the opportunity to discuss some of the latest methodologies developed by our team, focusing on predictive models for the progression of chronic diseases and the conduction of retrospective observational studies.
The discussions were highly productive and insightful. Dr. Seifi Ala provided valuable feedback and shared his expertise, which helped refine our approaches and identify new avenues for future research. The collaborative atmosphere facilitated a deeper understanding of the challenges and opportunities in leveraging real-world evidence to enhance clinical trials.
As our partnership with DMA continues to strengthen, we are excited about the potential to contribute significantly to the use of real-world evidence for complementing randomized controlled trials. Our joint efforts aim to improve the efficacy, safety, and cost-effectiveness of technologies designed to prevent and treat diabetes, ultimately benefiting patients and healthcare systems alike.
We look forward to continuing this fruitful collaboration and are eager to see the impact of our combined contributions to the REDDIE project.
